Emerging interventions, including aquaporin‐4 (AQP4) modulation, meningeal lymphatic regeneration, cervical deep lymphaticovenous anastomosis, and nonpharmacological approaches, are also discussed for their potential to shift AD therapeutics from symptom management to disease modification. The gene discussed is AQP4; the disease is Alzheimer disease.